This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Tue, 11/19/2024 - 15:57 Nov. 18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke. 16-18, 2024).
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrial fibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. Piccini, M.D.,
PFA is designed to address AFib, the most common arrhythmia in the US, with a growing patient population. Antiarrhythmic drugs are typically a poor solution for AFib, as their side effects can be debilitating. The operational and safety benefits are “nice,” but AFib ablation has never really been a dangerous procedure.
Given the irregular irregularity of beats #4-through 17 — Is this a run of AFib ( A trial Fib rillation ) with aberrant conduction? This raises the question if beats #4-thru-17 might represent a run of AFib with aberrant conduction? QUESTIONS: How would YOU interpret the ECG shown in Figure-1 ? What do YOU see?
mtaschetta-millane Tue, 07/16/2024 - 09:47 July 16, 2024 — Ultrahuman, a pioneer in wearable technology , launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. Ultrahuman Ring AIR is the first smart ring in the world to offer AFib detection.
Pulsed field ablation (PFA) was shown to be effective in treating patients with paroxysmal atrial fibrillation (AFib), with more patients free from atrial arrhythmias (AA) when compared with patients treated with thermal ablation, according to results from a secondary analysis of the ADVENT trial.
Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.
Affecting 60 million people worldwide 1 , the prevalence of atrial fibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.
Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared with oral anticoagulation, based on findings from the OPTION trial presented at AHA 2024 and simultaneously published in NEJM.
The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation. The PulseSelect gained CE Mark approval in November, and will launch commercially in early 2024.
In patients with high-risk atrial fibrillation (AFib) and stable coronary artery disease, endoxaban monotherapy when given as a long-term antithrombotic therapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, based on findings from the EPIC-CAD trial presented at ESC Congress 2024 in London and simultaneously (..)
An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany. Image courtesy: European Society of Cardiology.
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. AFib is the most common heart rhythm disorder, affecting more than 30 million patients worldwide.
Village doctors in rural China trained to manage the care of older adults with atrial fibrillation (AFib) and supported by AFib experts in tertiary hospitals through telemedicine lowered the risk of AFib-related adverse cardiovascular events by 36% over three years, based on findings from the MIRACLE-AF trial presented at ESC Congress 2024 in London. (..)
milla1cf Thu, 03/07/2024 - 20:10 March 7, 2024 — GE HealthCare will showcase its industry-leading portfolio of artificial intelligence ( AI )-enabled medical devices and digital solutions in Booth 2500 at the Health Information and Management Systems Society ( HIMSS ) Global Health Conference and Exhibition in Orlando, FL from March 11-15, 2024.
Image courtesy: Getty Images christine.book Wed, 07/24/2024 - 09:00 July 24, 2024 — Volta Medical , a health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists, has announced a Joint Development Agreement with GE HealthCare.
milla1cf Wed, 02/07/2024 - 18:05 February 7, 2024 — The Consumer Technology Association ( CTA ) and the American College of Cardiology ( ACC ) are announcing the release of their second industry framework for the use of consumer cardiovascular technology solutions in the screening and diagnosis for cardiovascular conditions.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
A short educational program for targeted at health care professionals in France, Germany, Italy, Poland, Spain and the UK increased patient-level adherence to guideline recommendations on atrial fibrillation (AFib) management, based on findings from the STEEER-AF trial presented at ESC Congress 2024 in London.
Performing additional catheter ablations targeting diseased myocardium along with the standard approach of pulmonary vein isolation (PVI) to treat persistent atrial fibrillation (AFib) did not reduce the recurrence of AFib at one year, based on findings from the SUPPRESS-AF trial presented at ESC Congress 2024 in London.
milla1cf Thu, 03/28/2024 - 07:28 March 28, 2024 — Biosense Webster, Inc., Based on the results from the admIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities, and become an important tool for the treatment of AFib." In the U.S., In the U.S.,
milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).
Treatment with the Type 2 diabetes medication metformin, lifestyle changes, or a combination of both did not improve atrial fibrillation (AFib) burden or progression when compared with standard care, according to preliminary late-breaking science presented Nov. 18 at the American Heart Association's Scientific Sessions 2024.
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
The American Heart Association (AHA) Congress 2024 , held from November 1618, marked a pivotal moment in cardiovascular and metabolic health. OPTION Trial : LAAC after AFib ablation was associated with lower risks of major bleeding compared to oral anticoagulation. Access the full study. View the study. Michos, MD , Christie M.
milla1cf Fri, 02/02/2024 - 17:02 February 2, 2024 — Biosense Webster, Inc. , The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1
Here are multiple examples. == MY Comment , by K EN G RAUER, MD ( 8/19 /2024 ): == "The patient has a pacemaker." Suboptimal filter settings is a major reason this may occur ( See My Comment in the January 13, 2024 post ). He did well. Smith: this can usually be seen on chest x-ray. large boxes ). Hz -to- 150 Hz setting.
milla1cf Fri, 02/02/2024 - 17:18 February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. million people in the United States by 2050 and 17.9
Getty Images milla1cf Tue, 02/27/2024 - 17:24 February 27, 2024 — Biosense Webster, Inc. , Atrial fibrillation ( AFib ) affects approximately 38 million patients globally, significantly increasing the risk of stroke1,2. The The acquisition of Laminar, Inc.
The rhythm in both tracings in Case #2 shows AFib with a controlled ventricular response ( with a PVC in the 2nd tracing ). Presumably the AFib is not a new rhythm — since new-onset AFib is usually associated with a rapid ventricular response. Another missed OMI by the False STEMI-NonSTEMI Dichotomy Don't miss them!!!
But I have seen AIVR in young people with trauma (see case below) So I sent it to Ken Grauer and here are his comments: = For clarity — I've reproduced in Figure-1 the ECG that Dr. Smith sent me ( Ken Grauer, MD — 3/7/2024 ). Figure-1: The ECG sent to Ken Grauer ( showing some semblance of "group" beating ).
s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. AFib Wakeup Call – A JACC study suggested that atrial fibrillation is far more prevalent than many thought.
The February 18, 2024 post — for PTA ( P ulse- T ap A rtifact ). The January 15, 2024 post — for an OMI despite lots of artifact! The April 6, 2023 post — excessive baseline artifact misdiagnosed as AFib ( instead of sinus rhythm with AV Wenckebach — as in Figure-4 in this post ). The September 15, 2023 post — for PTA.
Another vendor to watch in this space is Israeli start-up CardiaCare, currently developing a ‘world-first’ closed-loop, neuromodulation wearable for the non-invasive treatment for AFib. Fund raising activity should pick up in 2024, as interest rate stabilize and vendors, buoyed by further regulatory approvals, plot their routes to market.
Altered Mental Status, Bradycardia == MY Comment , by K EN G RAUER, MD ( 2/2 /2024 ): == Dr. Meyers began today’s case with the clinical challenge of asking you to identify the underlying cause of ECG #2. Is there a long QT? Is the QT appropriate for the temperature? How would you manage this patient? Baseline artifact is no longer present.
Continue Eliquis 5mg BID, should be continued for 3 months == MY Comment , by K EN G RAUER, MD ( 9/18 /2024 ): == I found the following aspects of today's case of special interest. Is longterm endurance-training a risk factor for AFib and AFlutter? == Why is Today's Initial Rhythm AFlutter?
Nearly a year after Bayer halted its OCEANIC-AF trial , the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors. Is asundexian really that much worse than apixaban for reducing stroke risks in AFib patients?
milla1cf Wed, 04/03/2024 - 18:55 April 3, 2024 — - Eko Health , a pioneer in applying artificial intelligence ( AI ) for early detection of heart and lung diseases, announces FDA clearance for its Low EF detection AI. For the first time, U.S.
The native QRS may be more obvious in one lead or another. == MY Comment , by K EN G RAUER, MD ( 5/30 /2024 ): == I was not taught about artifact in medical school. KEY Point: As per Dr. Frick: i ) Artifact is "alive and well" in 2024. The May XXX, 2024 post ( = Today's case by Dr. Frick ) — re Telemetry artifact that simulates PMVT.
That said — distinction between "classic" HCM vs the apical HCM for m may be useful because: i ) ECG findings tend to be different ( Lyon et al — Europace 20:102-112iii, 2018 ) ; — ii ) Echo appearance is different when hypertrophy localizes to the apex; and , iii ) There is a significantly greater incidence of AFib with apical HCM.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content